Prexa Pharmaceuticals Secures $7,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=89bae812-37aa-43c5-af6e-6ef38d17daef&Preview=1 - Date
5/11/2011 - Company Name
Prexa Pharmaceuticals - Mailing Address
184 High St. Boston, MA 02110 - Company Description
Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. - Website
http://www.prexainc.com - Transaction Type
Venture Equity - Transaction Amount
$7,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will allow thecompany to complete IND-enabling studies through Phase 1b clinical studies for its lead productcandidate PRX-12251. - M&A Terms
- Venture Investor
Advent Healthcare Ventures - Venture Investor
Shire Pharmaceuticals - Venture Investor
Undisclosed
